These Stocks Are Still Feeling The Heat From Elon Musk’s Twitter Blue Dumpster Fire
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk kicked off his first week at the helm of Twitter with a bang — but it backfired.<
After Elon Musk’s Twitter Blue Chaos, Platform Now ‘Rolling Out’ New Feature To Enable Companies Authenticate Users
Tesla Inc. (NASDAQ: TSLA) CEO and now Twitter chief Elon Musk has announced that the microblogging site will soon enable organizations to manage affiliated accounts.
Elon Musk’s Blue Check Verification Hurts: 8 Companies That Took A Hit From Twitter Account Impersonators
Elon Musk’s takeover of Twitter has only served to compound the social media platform’s woes, at least during the initial stage.
Twitter Blue Account Declares Eli Lilly Giving Away Free Insulin, Pharma Giant Says Its Fake
A fake account with the handle @EliLillyandCo posted last week on Twitter that Eli Lilly And Co (NYSE: LLY) is giving away free insulin.
Goldman Sachs Maintains Neutral on Eli Lilly, Raises Price Target to $313
Goldman Sachs analyst Chris Shibutani maintains Eli Lilly (NYSE:LLY) with a Neutral and raises the price target from $281 to $313.
Control Of Congress Up For Grabs In Midterms: 12 Stocks To Watch
As voters endeavor to select the congressional candidates they believe would best assist the U.S. in navigating through historical issues it is currently facing, investors are wondering what's going to happen to equities.
Lilly To Begin Rollout Of Tempo Personalized Diabetes Management Platform
Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging
Data shared through platform interface may help healthcare providers make
$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 26.17% on an annualized basis producing an average annual return of 33.67%. Currently, Eli Lilly has a market capitalization of $337.71 billion.
Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression, Data Shows
Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease.…
Wells Fargo Maintains Equal-Weight on Eli Lilly, Raises Price Target to $365
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Equal-Weight and raises the price target from $305 to $365.